Project Grant R21GM160921
- This federal Project Grant award of $1,638,033, provided by the National Institutes of Health (NIH) under the Biomedical Research and Research Training Program (CFDA 93.859), supports the development of a CRISPR-free mammalian recombineering system at the Scripps Research Institute. The project aims to characterize and optimize a bacterial recombinase system for efficiently conducting large-scale DNA insertions, deletions, and substitutions in mammalian cells without inducing cytotoxic...
- This $616,401 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research on enzyme recruitment and metabolic plasticity. The objective is to use biochemistry, evolution experiments, and -omics methods to investigate how cellular features impact enzyme recruitment, which is a key process enabling the evolution of new metabolic pathways. The research will leverage three...
- The National Institute of General Medical Sciences (NIGMS) awarded a $597,573 Project Grant under CFDA 93.859 - Biomedical Research and Research Training to The Ohio State University (OSU) with a project period from Jun 1, 2025 to Mar 31, 2030. The grant supports fundamental scientific research and advanced training focused on understanding the structure, dynamics, interactions, and function of large protein and protein-nucleic acid complexes that play key roles in human health and disease....
- This Project Grant from the National Science Foundation's Division of Molecular and Cellular Biosciences, under the Biological Sciences program (CFDA 47.074), provides $2,082,834 to The Ohio State University for research on bacterial genome engineering mechanisms. The university will study the interactions between the Red-Beta recombinase enzyme and single-stranded DNA binding protein in bacteria, using x-ray crystallography and cryo-electron microscopy to determine the three-dimensional...
- This $2,130,924 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports fundamental scientific research on the regulation of biological oscillators and rhythmic molecular and morphological processes at The Ohio State University. The project aims to advance understanding of the developmental regulation of oscillatory gene expression and protein activity, with a focus on the...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of engineered enzymes that can be activated to perform targeted modifications of cellular proteins. The $1,602,000 award to the Dana-Farber Cancer Institute, Inc. (DFCI) will fund research to design and apply novel autoinhibited enzymes that can toggle between inactive and active conformations in response...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $393,750 to The Ohio State University to develop a platform for discovering selective cleavable peptide prodrug linkers. The goal is to incorporate these linkers into multifunctional siderophore-based delivery systems to overcome limitations of existing siderophore-antibiotic conjugates and repurpose gram-positive antibiotics for...
- This Project Grant award, valued at $400,178.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the University of Nevada, Reno. The award, effective August 8, 2025, aims to enhance the protein engineering and design toolbox by exploring the relationships between protein sequence, structure, and function in multifunctional proteins. The research will focus on engineering designer protein...
- This National Science Foundation (NSF) Project Grant, awarded under the Mathematical and Physical Sciences (CFDA 47.049) program, provides $233,333 to The Ohio State University to develop and implement multifunctional DNA-based nanoscale devices. The goal is to detect genetic activity and control gene expression, particularly related to cell state and differentiated functions. The devices will enable mechanical control of gene regulation and provide insights into how chromatin structure and...
- This Project Grant award of $249,000.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) is to support research at Duke University to expand the capabilities of enzymes beyond their natural functions for synthesizing medicinally important chemical compounds. The key products or services to be delivered include engineering heme enzymes and methionine sulfoxide reductases to catalyze aminations and oxidations,...
This Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop novel tools for directed evolution of high-specificity, high-efficiency recombinases. The $408,633 award to The Ohio State University, granted on September 1, 2025, will support research to address the limitations of current substrate-linked directed evolution (SLIDE) methods for engineering tyrosine recombinases. The project focuses on developing SLIDE techniques that can provide both positive selection at a desired target site and negative selection against off-target sequences, in order to produce recombinases with high specificity and efficiency. This research is expected to enable the creation of more precise and effective recombinase tools for applications in genetic engineering and potential therapeutic uses. The project will be conducted at The Ohio State University and is scheduled for completion by August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $408.6k | 8/14/25 |